• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

术前促甲状腺激素(TSH)控制在 30-70mIU/L 能使分化型甲状腺癌患者对初始碘-131 清甲治疗有更好的反应。

A pre-ablative thyroid-stimulating hormone with 30-70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients.

机构信息

Center of Evidence-Based Medicine, Institute of Medical Sciences, the Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, China.

Department of Nuclear Medicine, the Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

出版信息

Sci Rep. 2021 Jan 14;11(1):1348. doi: 10.1038/s41598-020-80015-8.

DOI:10.1038/s41598-020-80015-8
PMID:33446744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7809467/
Abstract

Our aim was to clarify the optimum pre-ablative thyroid-stimulating hormone (TSH) level for initial radioiodine remnant ablation (RRA) in patients with differentiated thyroid carcinoma (DTC). From December 2015 to May 2019, 689 patients undergone RRA at Nuclear Medicine Department, Second Hospital of Shandong University were included in the study. Patients were categorized by their pre-ablative TSH level grouping of < 30, 30-70 and ≥ 70 mIU/L. Response to RRA were evaluated as complete response (including excellent and indeterminate response) and incomplete response (including biochemical and structural incomplete response) after a follow-up of 6-8 months. Multivariable binary logistic regression model was used to explore the optimum pre-ablative TSH level range and independent factors associated with response to RRA. Rates of complete response to RRA were 63.04%, 74.59% and 66.41% in TSH level groups of < 30, 30-70 and ≥ 70 mIU/L, separately. With multivariate analysis, the study found that pre-ablative TSH levels, gender and lymph node dissection were independent predictors of response to RRA. TSH between 30 and 70 mIU/L had a higher rate of complete response compared with TSH < 30 mIU/L, OR 0.451 (95% CI 0.215-0.958, P = 0.036). A pre-ablative TSH level of 30-70 mIU/L was appropriate for patients with DTC to achieve a better response to RRA.

摘要

我们旨在明确分化型甲状腺癌(DTC)患者初始放射性碘残余消融(RRA)前促甲状腺激素(TSH)的最佳水平。2015 年 12 月至 2019 年 5 月,共有 689 例在山东大学第二医院核医学科行 RRA 的患者纳入本研究。根据患者的预消融 TSH 水平分为<30、30-70 和≥70 mIU/L 组。在随访 6-8 个月后,评估 RRA 反应为完全缓解(包括极好和不确定反应)和不完全缓解(包括生化和结构不完全缓解)。采用多变量二项逻辑回归模型探讨最佳预消融 TSH 水平范围和与 RRA 反应相关的独立因素。TSH<30、30-70 和≥70 mIU/L 组的 RRA 完全缓解率分别为 63.04%、74.59%和 66.41%。多因素分析发现,预消融 TSH 水平、性别和淋巴结清扫术是 RRA 反应的独立预测因素。与 TSH<30 mIU/L 相比,TSH 在 30-70 mIU/L 时完全缓解率更高,OR 0.451(95%CI 0.215-0.958,P=0.036)。对于 DTC 患者,30-70 mIU/L 的预消融 TSH 水平可获得更好的 RRA 反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5faa/7809467/9bd725cec2dc/41598_2020_80015_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5faa/7809467/9bd725cec2dc/41598_2020_80015_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5faa/7809467/9bd725cec2dc/41598_2020_80015_Fig1_HTML.jpg

相似文献

1
A pre-ablative thyroid-stimulating hormone with 30-70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients.术前促甲状腺激素(TSH)控制在 30-70mIU/L 能使分化型甲状腺癌患者对初始碘-131 清甲治疗有更好的反应。
Sci Rep. 2021 Jan 14;11(1):1348. doi: 10.1038/s41598-020-80015-8.
2
Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?短程甲状腺激素抑制治疗在分化型甲状腺癌患者放射性碘清甲治疗中的作用
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1218-1223. doi: 10.1007/s00259-018-3955-x. Epub 2018 Feb 19.
3
A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.重组人促甲状腺素作为放射性碘甲状腺残余组织消融术前准备的有效性回顾性研究。
J Nucl Med. 2002 Nov;43(11):1482-8.
4
TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer.促甲状腺激素(TSH)≥30 mU/L 可能并非分化型甲状腺癌患者 131I 残余消融成功所必需的。
Eur Thyroid J. 2023 Jun 12;12(4). doi: 10.1530/ETJ-22-0219. Print 2023 Aug 1.
5
The efficacy of radioiodine remnant ablation for differentiated thyroid carcinoma patients with an incomplete thyroidectomy.放射性碘残留消融术对甲状腺次全切除术后分化型甲状腺癌患者的疗效。
Q J Nucl Med Mol Imaging. 2016 Sep;60(3):280-4. Epub 2014 Sep 5.
6
Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.内源性和外源性促甲状腺激素联合刺激后分化型甲状腺癌的放射性碘残留消融
Nuklearmedizin. 2012;51(3):67-72. doi: 10.3413/Nukmed-0432-11-10. Epub 2012 Feb 1.
7
Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.较高的消融前血清促甲状腺激素水平可预测分化型甲状腺癌患者放射性碘消融的有效性。
Nucl Med Commun. 2017 Mar;38(3):222-227. doi: 10.1097/MNM.0000000000000640.
8
Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment.对已进行R0切除的低风险分化型甲状腺癌患者进行放射性碘残留消融是过度治疗。
Cancer Med. 2015 Jul;4(7):1031-8. doi: 10.1002/cam4.443. Epub 2015 Mar 9.
9
Evaluation of ablation of thyroid remnants with 1850 MBq iodine-131 in 67 patients with thyroid cancer.用1850MBq碘-131对67例甲状腺癌患者的甲状腺残余组织进行消融的评估。
Q J Nucl Med Mol Imaging. 2019 Mar;63(1):68-75. doi: 10.23736/S1824-4785.16.02839-9. Epub 2016 Apr 29.
10
Strong Neck Accumulation of 131I Is a Predictor of Incomplete Low-Dose Radioiodine Remnant Ablation Using Recombinant Human Thyroid-Stimulating Hormone.131I在颈部的浓聚是使用重组人促甲状腺激素进行低剂量放射性碘残留消融不完全的预测指标。
Medicine (Baltimore). 2015 Sep;94(39):e1490. doi: 10.1097/MD.0000000000001490.

引用本文的文献

1
Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta-analysis.甲状腺癌患者初始放射性碘治疗延迟超过 3 个月对临床反应和总生存率无影响:一项队列研究和荟萃分析。
Cancer Med. 2022 Jun;11(12):2386-2396. doi: 10.1002/cam4.4607. Epub 2022 Feb 18.
2
Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma.分子证据显示促甲状腺激素干预会增加发生放射性碘难治性分化型甲状腺癌的风险。
Cancer Cell Int. 2022 Feb 3;22(1):61. doi: 10.1186/s12935-022-02484-3.

本文引用的文献

1
Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas.放射性碘难治评分:用于预测术后放射性碘难治性分化型甲状腺癌的多变量预测模型。
Cancer Med. 2018 Nov;7(11):5448-5456. doi: 10.1002/cam4.1794. Epub 2018 Sep 27.
2
Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?短程甲状腺激素抑制治疗在分化型甲状腺癌患者放射性碘清甲治疗中的作用
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1218-1223. doi: 10.1007/s00259-018-3955-x. Epub 2018 Feb 19.
3
Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
较高的消融前血清促甲状腺激素水平可预测分化型甲状腺癌患者放射性碘消融的有效性。
Nucl Med Commun. 2017 Mar;38(3):222-227. doi: 10.1097/MNM.0000000000000640.
4
Thyroid cancer.甲状腺癌。
Lancet. 2016 Dec 3;388(10061):2783-2795. doi: 10.1016/S0140-6736(16)30172-6. Epub 2016 May 27.
5
In Patients With Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy.对于低危到中危甲状腺癌患者,促甲状腺激素(TSH)水平达到 30 μIU/mL 并不足以实现更好的 131I 治疗反应。
Clin Nucl Med. 2016 Jun;41(6):454-8. doi: 10.1097/RLU.0000000000001167.
6
Endogenous TSH levels at the time of I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality.I消融时的内源性促甲状腺激素水平不影响消融成功率、无复发生存率或分化型甲状腺癌相关死亡率。
Eur J Nucl Med Mol Imaging. 2016 Feb;43(2):224-231. doi: 10.1007/s00259-015-3223-2. Epub 2015 Oct 23.
7
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.2015年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南:美国甲状腺协会甲状腺结节和分化型甲状腺癌指南工作组
Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.
8
Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.分化型甲状腺癌治疗后的长期结局:1987 - 2012年NTCTCS登记分析
J Clin Endocrinol Metab. 2015 Sep;100(9):3270-9. doi: 10.1210/JC.2015-1346. Epub 2015 Jul 14.
9
Strategies of radioiodine ablation in patients with low-risk thyroid cancer.低危甲状腺癌患者的碘 131 消融策略。
N Engl J Med. 2012 May 3;366(18):1663-73. doi: 10.1056/NEJMoa1108586.
10
Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial.分化型甲状腺癌患者术后残留甲状腺组织消融中低剂量与高剂量放射性碘的比较:一项大型随机临床试验
Nucl Med Commun. 2012 Mar;33(3):275-82. doi: 10.1097/MNM.0b013e32834e306a.